US stocks finished mostly lower on Thursday as yet more tariff uncertainty weighed on risk appetite, while investors digested another flurry of economic data and corporate earnings.

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

“Dividend traps” are stocks that lure investors with the promise of a substantial payout that ends up as unsustainable. Some ...

Wall Street trading got off to a mixed start on Tuesday as traders turned their attention to a flurry of corporate earnings.